Strzelczyk, Adam http://orcid.org/0000-0001-6288-9915
Schubert-Bast, Susanne http://orcid.org/0000-0003-1545-7364
Funding for this research was provided by:
Zogenix
Johann Wolfgang Goethe-Universität, Frankfurt am Main
Article History
Accepted: 7 September 2022
First Online: 4 October 2022
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL. Medical writing assistance was funded by Zogenix GmbH (now a part of UCB).
: Adam Strzelczyk reports personal fees and grants from Angelini Pharma, Desitin Arzneimittel, Eisai, GW Pharmaceuticals companies, Marinus Pharmaceuticals, Precisis, UCB Pharma, UNEEG Medical and Zogenix. Susanne Schubert-Bast reports personal fees from Eisai, Desitin Pharma, GW Pharmaceuticals companies, LivaNova, UCB Pharma and Zogenix.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Both authors reviewed the literature, drafted the manuscript, generated the figures and assume full responsibility for the final publication.